Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.

Pharmaceutics · 2023 · PMC10053212 · PMID 36986707

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Lentiviral Vector-Based Vaccination in Preclinical Models LV-based vaccination against infectious diseases and malignancies have consistently demonstrated the induction of strong humoral and cellular immune responses, accompanied by highly significant protection in preclinical animal models.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.